Up-regulation of Caveolae and Caveolar Constituents in Multidrug-resistant Cancer Cells
Overview
Authors
Affiliations
Cancer chemotherapy often results in the development of multidrug resistance (MDR), which is commonly associated with overexpression of P-glycoprotein (P-gp), a plasma membrane drug efflux ATPase. It was shown recently that glycosphingolipids are elevated in MDR cells. Sphingolipids are major constituents of caveolae and of detergent-insoluble, glycosphingolipid-rich membrane domains. Here we report that multidrug-resistant HT-29 human colon adenocarcinoma cells exhibit a 12-fold overexpression of caveolin-1, a 21-kDa coat/adaptor protein of caveolae. Similar observations were made in adriamycin-resistant MCF-7 human breast adenocarcinoma cells. Caveolin-2 expression is also up-regulated in MCF-7-AdrR cells, but neither caveolin-1 nor caveolin-2 were detected in MCF-7 cells stably transfected with P-gp. The up-regulation of caveolins is associated with a 5-fold increase in the number of caveolae-like structures observed in plasma membrane profiles of HT-29-MDR cells and with the appearance of a comparable number of caveolae in MCF-7-AdrR cells. A significant fraction (approximately 40%) of cellular P-gp is localized in low density detergent-insoluble membrane fractions derived from either HT-29-MDR or MCF-7-AdrR cells. The distribution of recombinant P-gp in stably transfected MCF-7 cells was similar, even though these cells do not express caveolins and are devoid of caveolae. The possibility that caveolae contribute to the multidrug resistance and thus are co-selected with P-gp during the acquisition of this phenotype is discussed.
Teruel I, Castella E, Recalde S, Vinas G, Petit A, Trigueros M Int J Mol Sci. 2024; 25(22).
PMID: 39596307 PMC: 11594706. DOI: 10.3390/ijms252212241.
Gutay-Toth Z, Gellen G, Doan M, Eliason J, Vincze J, Szente L Int J Mol Sci. 2023; 24(15).
PMID: 37569709 PMC: 10419235. DOI: 10.3390/ijms241512335.
Eng M, Imperio G, Bloise E, Matthews S Cell Mol Life Sci. 2022; 79(8):415.
PMID: 35821142 PMC: 11071850. DOI: 10.1007/s00018-022-04432-w.
Luo F, Li J, Liu J, Liu K Cancer Gene Ther. 2022; 29(11):1707-1719.
PMID: 35750753 DOI: 10.1038/s41417-022-00493-y.
Lee W, Frank T Cancer Drug Resist. 2022; 4(2):424-452.
PMID: 35582031 PMC: 9019277. DOI: 10.20517/cdr.2020.114.